Summary
Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript
Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
Hypera S.A. (OTCPK:HYPMY) Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Breno Toledo Pires de Oliveira - Chief Executive Officer Adalmario Ghovatto Satheler do Couto - Investor Relations Officer Ramon Sanches Frutuoso Silva - Chief Financial Officer Conference Call Participants Joseph Giordano - JP Morgan Robert Ford - Bank of America Mauricio Cepeda - Morgan Stanley Vinicius Figueiredo - Itau BBA Samuel Alves - BTG Pactual Operator Good morning, ladies and gentlemen.
Hypera: Short-Term Pain For Long-Term Gain
Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have caused a sharp drop in Hypera's stock over the past five years. The company launched a plan to boost cash flow via reduced receivables and inventory, aiming for long-term profitability but facing short-term earnings challenges.
Hypera S.A. (HYPMY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hypera S.A. ever had a stock split?
Hypera S.A. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Breno Toledo Pires de Oliveira CEO | OTC PINK Exchange | 44914U106 CUSIP |
| BR Country | 10,564 Employees | 6 Jul 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Hypera S.A. is a prominent pharmaceutical company based in Brazil, known for its expansive portfolio of healthcare products. Initially established in 2001 under the name Hypermarcas S.A., the company underwent a name change to Hypera S.A. in February 2018, signifying a new era in its history. Operating primarily within Brazil, Hypera S.A. specializes in developing, producing, and marketing a wide range of pharmaceutical products, including prescription medications, over-the-counter (OTC) drugs, and nutritional supplements. Its mission centers on delivering high-quality healthcare solutions to improve the well-being of its consumer base. Headquartered in São Paulo, Brazil, Hypera S.A. stands as a leading entity in the Latin American pharmaceutical landscape.
Products and Services
Hypera S.A. offers an extensive variety of products and services categorized into several segments: pharmaceuticals, consumer health products, and nutritional and vitamin supplements. Listed below are some of the company's notable products and brands:
- Pharmaceutical Products: The company's strong pharmaceutical portfolio includes prescription medications like Adacne, Addera, Celestamine, and Diprosone among others, catering to various healthcare needs from dermatological solutions to anti-inflammatory agents. They also offer a range of products such as Deciprax, Emprol XR, and Max Sulid, focusing on providing comprehensive healthcare remedies.
- Sun Protection and Skincare: Under the Mantecorp Skincare brand, Hypera S.A. provides a spectrum of sun protection and moisturizing skin care products, addressing the growing consumer needs for comprehensive dermatological care and protection against harmful UV rays.
- Consumer Health Products: The company's consumer health sector is symbolized by household names like Apracur, Benegrip, and Neosaldina, catering to everyday health issues such as cold and flu, digestive discomfort, and pain relief. The Neo Química brand is renowned for offering a range of similar and generic drugs, expanding the company’s reach in the consumer health market.
- Nutritional and Vitamin Supplements: Recognizing the importance of dietary supplements in modern healthcare, Hypera S.A. markets products under the Tamarine, Vitasay, and Zero-Cal brands. These offer solutions for nutritional deficiencies and support overall health and wellness.
- Generic Medicines: Emphasizing accessibility and affordability, Hypera S.A. provides a wide array of generic medicines including Hydroxyzine, Naproxene, and Omeprazole. This segment ensures patients have access to essential medications at lower costs while maintaining high-quality standards.
